Abstract: A switching control circuit for use in controlling a resonant flyback power converter generates a first driving signal and a second driving signal. The first driving signal is configured to turn on the first transistor to generate a first current to magnetize a transformer and charge a resonant capacitor. The transformer and charge a resonant capacitor are connected in series. The second driving signal is configured to turn on the second transistor to generate a second current to discharge the resonant capacitor. During a power-on period of the resonant flyback power converter, the second driving signal includes a plurality of short-pulses configured to turn on the second transistor for discharging the resonant capacitor. A pulse-width of the short-pulses of the second driving signal is short to an extent that the second current does not exceed a current limit threshold.

Abstract: A resonant flyback power converter includes: a first and a second transistors which form a half-bridge circuit for switching a transformer and a resonant capacitor to generate an output voltage; a current-sense device for sensing a switching current of the half-bridge circuit to generate a current-sense signal; and a switching control circuit generating a first and a second driving signals for controlling the first and the second transistors. The turn-on of the first driving signal controls the half-bridge circuit to generate a positive current to magnetize the transformer and charge the resonant capacitor. The turn-on of the second driving signal controls the half-bridge circuit to generate a negative current to discharge the resonant capacitor. The switching control circuit turns off the first transistor when the positive current exceeds a positive-over-current threshold, and/or, turns off the second transistor when the negative current exceeds a negative-over-current threshold.

Abstract: A method of preparing a very slightly soluble drug with solid composition includes the following steps: (a) adding a very slightly soluble drug into an organic solvent and polysorbate to form a first solution; (b) adding the first solution into a second solution and a pharmaceutically acceptable excipient, wherein the second solution comprises water or SLS, and a volume ratio of the first solution and the second solution is between 8:1 and 1:1; and (c) drying and compressing the mixture in step (b) to form a very slightly soluble drug with solid composition.

Abstract: A method of preparing a very slightly soluble drug with solid composition includes the following steps: (a) adding a very slightly soluble drug into an organic solvent and polysorbate to form a first solution; (b) adding the first solution into a second solution and a pharmaceutically acceptable excipient, wherein the second solution comprises water or SLS, and a volume ratio of the first solution and the second solution is between 8:1 and 1:1; and (c) drying and compressing the mixture in step (b) to form a very slightly soluble drug with solid composition.

Abstract: A sustained release alfuzosin hydrochloride formulation contains alfuzosin hydrochloride as about 1% to about 5% by weight of the formulation, hydrophilic polymers as about 35% to about 75% by weight of the formulation, hydrophobic polymers as about 10% to about 30% by weight of the formulation, disintegrating agents as 10% to 30% by weight of the formulation and a binder as about 2% to about 12% by weight of the formulation. The hydrophilic and hydrophobic polymers are used as the release-modulating agent to control the dissolution profile of the alfuzosin hydrochloride formulation so that the formulation releases alfuzosin hydrochloride slowly and continuously as the formulation passed through the gastrointestinal tract. The present invention also relates to a method for preparing the above formulation.

Abstract: A composition of human interferon-alpha (IFN-?) subtypes produced from human lymphoblastoid cells is disclosed. These purified IFN-? composition comprise higher specific activities and may be applied in the treatment of cancers, viruses, and immuno diseases.